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ttp://dx.doi.org/10.1016/j.ajpath.2014.11.025Platelet-activating factor (PAF) is a powerful proinﬂammatory mediator that displays an exceedingly
diverse spectrum of biological effects. Importantly, PAF is shown to participate in a broad range of
pathologic conditions. This review focuses on the role that PAF plays speciﬁcally in the pathophysiology
of the kidney, the organ that is both a source and a target of PAF. Renal mesangial cells are responsible
for glomerular PAF generation and, ultimately, are the victims of its excessive production. Mesangial
pathology is widely acknowledged to reﬂect glomerular damage, which culminates in glomerulosclerosis
and proteinuria. Therefore, modulation of mesangial cell responses would offer a pathophysiology-
based therapeutic approach to prevent glomerular injury. However, the currently available therapeutic
modalities do not allow for targeted intervention into these processes. A more profound understanding
of the mechanisms that govern PAF metabolism and signaling in mesangial cells is important, because it
could facilitate the quest for improved therapies for renal patients on the basis of PAF as a drug target.
(Am J Pathol 2015, 185: 888e896; http://dx.doi.org/10.1016/j.ajpath.2014.11.025)Supported by NIH, National Institute of General Medical Sciences grant
GM076468 and National Institute of Aging grant AG038070.
Disclosures: None declared.A substantial body of literature is available on the role of
platelet-activating factor (PAF) in renal pathophysiology.
After the discovery of PAF by Jacques Benveniste,1 a
publication burst in the ﬁeld of PAF in kidney research was
observed. We summarize previous ﬁndings and point out
conﬂicting reports and information gaps to revive the
research interest with this review. Taking into account the
recently acknowledged central role of mesangial cells in
many forms of glomerular injury and the identiﬁcation of a
gene that, when overexpressed in mesangial cells, leads to
an increase in PAF and mesangial matrix expansion, we set
the boundaries of this review to focus on the role of PAF in
mesangial pathophysiology.
Platelet-Activating Factor
PAF (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is
a mediator of inﬂammation. By its chemical nature, PAF
belongs to the ether phospholipids.2 Strictly speaking,
PAF is not a single entity but rather a generic collective
term for a heterogeneous class of molecular species with
different saturated or mono-/di-unsaturated alkyl, acyl, or
alkenyl chains attached through ether linkage at the sn-1stigative Pathology.
.position of the glycerol backbone3,4 (Figure 1). The
structural diversity translates into differences in biolog-
ical potency, with the predominant and most biologically
active species of PAF containing C16:0, C18:0, or C18:1
alkyl groups.4,5
PAF is a proinﬂammatory autacoid (a local hormone with
paracrine effects) with pleiotropic effects. As a matter of fact,
the term platelet-activating factor is a misnomer, because the
effect of PAF on physiologic processes is not limited to and
goes far beyond degranulation of platelets, the ﬁrst effect that
was documented.1,6,7 Diverse biological activities are
ascribed to PAF, and it was found to be involved in the
pathogenesis of a wide range of diseases.8e10
In addition to the effects of the structural variation, the
broad spectrum of PAF effects is achieved through a broad
range of downstream mediators (Figure 2), via which PAF
can elicit many of the reactions of inﬂammation and allergy,
including enhanced leukocyte adhesion, chemotaxis,
leukocyte degranulation, respiratory burst, and increased
vascular permeability.11e13
Figure 1 General molecular structure of platelet-activating factor, with
R indicating the side chain that can either be a saturated or mono-/
di-unsaturated alkyl, acyl, or alkenyl group.
Figure 2 The upstream (green) and the downstream (blue) mediators
of PAF. Various mediators can regulate PAF. PAF exerts its effect on a broad
range of downstream mediators to elicit inﬂammation and allergy
reactions, including enhanced leukocyte adhesion, chemotaxis, leukocyte
degranulation, respiratory burst, and increased vascular permeability.
AngII, angiotensin II; LDLR, low-density lipoprotein receptor; PAF,
platelet-activating factor; PKC, protein kinase C; PLA2, phospholipase A2;
PLC, phospholipase C; TGF-b, transforming growth factor-b; TNF-a, tumor
necrosis factor-a.
PAF and Mesangial CellsA number of cell types, such as endothelial, inﬂamma-
tory, and renal mesangial cells, are shown to produce PAF,
which can be synthesized via two distinct enzymatic routes,
namely the remodeling pathway and the de novo
pathway.2,14,15 The remodeling pathway involves a struc-
tural modiﬁcation of 1-O-etherelinked membrane phos-
pholipids in which the action of cytoplasmic phospholipase
A2 yields a biologically inactive lyso-PAF, which is then
acetylated and leads to the formation of PAF16,17 (Figure 3A).
In the de novo pathway, PAF synthesis occurs from simpler
molecules, such as dihydroxyacetonephosphate, in several
steps18e20 (Figure 3B).
PAF is generally regarded as a highly metabolically
unstable compound, because it is rapidly converted to bio-
logically inactive lyso-PAF by cytosolic and plasma PAF-
acetylhydrolases.21e23 This is illustrated by the fact that
exogenously added PAF at a concentration as low as 109
mol/L has a half-life of only 5 minutes in the plasma of
normal subjects.24 Similar results were obtained in animal
experiments. However, it is debatable whether the rapid
disappearance from circulation is indicative of its catabolism
or redistribution to peripheral tissues. Furthermore, addi-
tional PAF degradation mechanisms exist that involve
phospholipases C, D, and A1.
4
The Kidney as the Source of PAF
Although numerous cell types are able to generate PAF, the
kidney is an important, if not main, source of PAF pro-
duction in the body because PAF is virtually undetectable in
the blood of anephric patients and experimental animals that
have undergone bilateral nephrectomy.25 This is further
supported by the direct experimental evidence of PAF
release by the isolated perfused kidney.26
All of the elements required for PAF formation are present
in the kidney. Considerable activity of PAF biosynthesis key
enzymes, such as acetyl-CoA:lyso-PAF acetyltransferase5,27
of the remodeling pathway and cholinephosphotransferase20
of the de novo pathway, is found in renal tissue. Production ofThe American Journal of Pathology - ajp.amjpathol.orgPAF in the kidney can potentially be attributed to inﬁltrating
inﬂammatory cells and resident renal cells. Validity of the
latter is underscored because increased PAF production is
detected in human idiopathic nephrotic syndrome and
experimental puromycin aminonucleoside nephrosis,28,29
forms of renal damage without glomerular leukocyte inﬁl-
tration. Among the intrinsic renal cell types, glomerular
mesangial and medullary interstitial cells can generate PAF.
PAF is detected in the urine, and its levels are found to be
elevated in renal patients and experimental nephrosis
models compared with healthy subjects.28,30e33 This fact
has two important implications. First, it supports the notion
of the predominantly renal origin of PAF. The strong cor-
relation between kidney and urinary concentration values28
and the poor recovery of systemically circulating PAF in the
urine, even in the case of increased glomerular perme-
ability,31 conﬁrms its renal origin. Second, it reveals a
biomarker capacity of PAF, because its presence in the urine
at measurable concentrations that escalate in the renal dis-
ease constitutes a potential for a noninvasive diagnostic and/
or prognostic test.
The Kidney as the Target for PAF
PAF exerts its effects on target cells via a speciﬁc G pro-
teinecoupled receptor, the PAF receptor (PAFR).34 In the
kidney, PAFR mRNA is ubiquitously expressed. There is a
gradient of its expression levels being the richest in the renal889
Figure 3 The two platelet-activating factor biosynthesis pathways: the remodeling pathway (A) and the de novo pathway (B).
Reznichenko and Korstanjecortex, with a lesser amount in the outer medulla, followed
by the inner medulla. Within the nephron, the glomerulus
demonstrates the highest PAFR expression, followed by the
proximal tubule, with the other tubular segments displaying
lower levels.35 In a unilateral ureter obstruction model,
PAFR expression increases almost 70-fold, and the lack of
PAFR (by gene knockout) in this model reduces proﬁbrotic
signaling, collagen deposition, and albuminuria.36 To date,
PAFR is the only receptor known to bind species of the PAF
class of molecules.
Exogenous PAF infusion affects renal hemodynamics and
glomerular permeability, resulting in changes in ﬁltration rate
and proteinuria. Although the systemic hypotensive effect of
PAF is uniform across different experimental species, the
renal vascular response may be species speciﬁc. In the rat,
systemically injected PAF causes renal vasodilation, leading
to a dose-dependent fall in glomerular ﬁltration rate (GFR)
and renal blood ﬂow. Infusion of PAF directly into the renal
artery reproduces these effects independently of systemic
hemodynamics; thus, this effect is likely to be direct and not
secondary due to PAF-mediated systemic blood pressure
decrease.37,38 Similar results were observed in the isolated
perfused rat kidney model. However, in the dog, intrarenal
PAF administration elicits renal vasoconstriction and has no
effect on the vasculature of the isolated perfused cat and
rabbit kidneys.10,37 In addition, in the isolated perfused rat
kidney, infusion of PAF results in an approximately sixfold
increase in proteinuria over basal values.39 Consistently, in
the experimental puromycin aminonucleoside nephrosis
model, PAF production in the kidney increases and peaks
before maximal proteinuria,40 supporting a mechanistic role
of PAF in the development of proteinuria.
PAF is a major mediator of antibody- and complement-
mediated glomerular injury, as shown in experimental and
human studies. PAF is implicated in antithymocyte antibody-
induced glomerular damage and other experimental models of
immune renal damage,10,41 and in patients with lupus nephritis
and IgA nephropathy.32 The mechanism underlying PAF
involvement in immune-mediated renal pathophysiologic890processes includes, among others, stimulation of monocyte
chemoattractant protein-1 glomerular expression,42 thus favor-
ing inﬂammatory cell inﬂux.
Experimental studies have shown that PAF participates in
the development of kidney graft dysfunction, namely trans-
plant rejection,43,44 chronic transplant nephropathy,45 and
immunosuppressive drug-mediated nephrotoxicity.46,47 The
experimental evidence suggests that the plausible mechanisms
of PAF effects in the transplantation setting are hemodynamic
and immune, such as antibody- and complement-mediated
injury. PAF production is signiﬁcantly enhanced in rejecting
renal allografts in experimental animal models,48 whereas
administration of PAF receptor blockers, even with no
immunosuppressive therapy, has a beneﬁcial effect on trans-
plant function as measured by GFR and renal blood ﬂow and
also decreases thromboxane A2 production by the graft and
complement activation.43 The effect of PAF antagonists on
histologic outcome is, however, unclear, because different
studies report disparate results about the effect on inﬂamma-
tory inﬁltration.
PAF is implicated in drug-related renal damage of
different causes, such as cyclosporin A (CsA),46 glycerol,49
gentamicin, and cisplatin.44,47 Beneﬁcial effects of PAF
antagonists on drug-related nephrotoxicity are demon-
strated in experimental studies. Interestingly, in animal
models, PAF injection induces similar hemodynamic ef-
fects to those observed with CsA. PAF is suggested to be
involved in CsA acute nephrotoxicity. However, the rela-
tion between PAF and CsA is not straightforward but rather
bidirectional. On one hand, CsA induces an increase in
PAF synthesis in mesangial cells in vitro. On the other
hand, when PAF production is already pathologically
elevated as a result of an experimental nephrosis, CsA
decreases it.29
Fibrosis due to extracellular matrix overproduction is a
key feature of progressive renal disease, regardless of the
primary cause. PAF may participate ubiquitously in renal
ﬁbrosis across all of the kidney structural compartments,
including the glomerulus and the tubulointerstitial space.ajp.amjpathol.org - The American Journal of Pathology
PAF and Mesangial CellsActing on renal cells, it triggers a molecular cascade of a
large array of proinﬂammatory and proﬁbrotic agents that
induce the sclerotic process. PAF up-regulates matrix pro-
teins in cultured mesangial cells,50 tubular epithelial cells,
and interstitial ﬁbroblasts.51 Among the downstream mo-
lecular effectors of PAF, arachidonic acid metabolites,
thromboxanes, prostacyclin, and transforming growth factor
(TGF)-b up-regulate extracellular matrix production that
manifest in ﬁbrosis.
PAF and Mesangial Cells
Mesangial cells are believed to be a major source of
glomerular PAF generation because in culture they generate
almost 10 times as much bioactive PAF per milligram of
protein compared with isolated glomeruli.5 Generation of
PAF by mesangial cells in vivo could have important impli-
cations for glomerular function, because PAF exerts a
multitude of effects on renal cells as reviewed here. However,
physiologic and pathophysiologic stimuli for PAF formation
by mesangial cells in vivo remain largely unknown and
warrant further investigation.
Mesangial PAF Metabolism
Mesangial cells are equipped with both biosynthesis and
degradation mechanisms of PAF metabolism.52,53 The
simultaneous presence of the counterbalancing mechanisms
strategically positions mesangial cells in charge of glomer-
ular PAF homeostasis.
Renal mesangial cells possess the complete enzymatic
machinery for PAF synthesis through both the remodeling and
the de novo pathways. Initially, it was shown that cultured
mesangial cells acetylated lyso-PAF to PAF, that is, produced
PAF through the remodeling pathway.5,16 Subsequently,
expression and activity of the de novo pathway enzymes in
mesangial cells was demonstrated experimentally.54 Func-
tionally, the two biosynthetic pathways are believed to serve
different purposes: the de novo route provides constitutive
production to maintain a certain basal level, whereas the
shorter remodeling pathway functions to rapidly up-regulate
PAF in response to pathologic triggers. Accordingly,
cultured mesangial cells are shown to produce PAF both in
quiescence and on stimulation with calcium ionophore
A23187, IgG, IL-1, tumor necrosis factor (TNF)-a,55,56
endotoxin,57 lipopolysaccharide,58 and other triggers of
inﬂammation. Of note, some studies report no PAF production
by mesangial cells under basal conditions,59 which might,
however, reﬂect technical limitation of its detection rather than
true absence. Evidence that PAF is newly synthesized after
stimulation is obtained by using radioactive precursors.
Consistent with the induction of PAF production via the
remodeling pathway, the enzymatic activity of acetyl-
CoA:lyso-PAF acetyltransferase increases multifold on chal-
lenging mesangial cells with proinﬂammatory stimuli.55
Interestingly, the increase of acetyltransferase activity doesThe American Journal of Pathology - ajp.amjpathol.orgnot depend on protein synthesis, suggesting a role for post-
transcriptional regulation mechanism.
PAF is a potent bioactive molecule that suggests the
existence of regulatory mechanisms to control and restrict
the biological actions of this powerful proinﬂammatory
mediator. How negative regulation is achieved under
physiologic conditions in largely unknown, but it is shown
experimentally that certain biomolecules display inhibiting
effect on mesangial PAF production. Plasma a1-proteinase
inhibitor suppresses induction of the remodeling pathway of
PAF synthesis in mesangial cells by preventing activation of
its key enzymes, phospholipase A2 and acetyl-CoA:lyso-
PAF acetyltransferase.55 Experimental hyperinsulinemia
reduces PAF levels by decreasing renal synthesis and
increasing plasma degradation of PAF through inhibition of
acetyltransferase activity and increasing plasma acetylhy-
drolase activity, respectively.60 PAF and nitric oxide have a
bidirectional effect on each other’s synthesis in mesangial
cells: inhibition of nitric oxide synthase induces synthesis of
PAF, which is conversely inhibited by nitric oxidegenera-
tion.61 Of note, nitric oxide synthase blockade triggers both
spontaneous and induced PAF synthesis.
Once synthesized, PAF does not accumulate in the cell, but
it is secreted. Mesangial cells secrete PAF via an active
transport mechanism that is mediated by multidrug resistance
P-glycoproteins.62,63 Both spontaneous (basal) and induced
(triggered by relevant stimuli) release of PAF occurs via this
mechanism. It is unknown whether the regulation of PAF
secretion is achieved independently of its production or
whether the same mechanisms that orchestrate PAF biosyn-
thesis direct its transport by a certain feedback loop.
Mesangial cells catabolize PAF with acetylhydrolases.
Besides the intracellularly present cytosolic enzymes, ace-
tylhydrolase activity is detected on the outer surface of
cultured mesangial cells.53 Mesangial acetylhydrolases may
constitute a defensive mechanism that protects mesangial and
other glomerular cells from the deleterious effects of locally
generated PAF. It is, therefore, important to investigate the
regulation of PAF inactivation in mesangial cells.
PAF Effects on Mesangial Cells
Mesangial cells express PAFR on their surface, which renders
them a target for systemically circulating PAF and autocrine
PAF.34,64 PAFR mRNA expression by mesangial cells is
responsive to PAF concentration, although the direction of the
effect of such homologous regulation is questionable because
different investigators reported disparate trends.64,65 The
controversial results obtained despite the use of comparable
concentrations of PAF can be explained by the nonoverlap-
ping time frames of the experiments, indicating that the
regulation of PAFR expression by PAF might be biphasic or
multiphasic. In addition, existence of additional regulators
cannot be excluded. PAF stimulates multiple signaling path-
ways in cultured mesangial cells,66 leading to arachidonate
release and subsequent prostanoid generation,67 leukocyte891
Figure 4 Schematic of the renal effects of PAF that culminates in glomerulosclerotic kidney damage. GBM, glomerular basement membrane; LDL,
low-density lipoprotein; PAF, platelet-activating factor.
Reznichenko and Korstanjerecruitment,61 mesangial cell contraction,56,67e71 intracellular
lipid accumulation,64 and matrix production.50 Although the
exact sequence and/or interplay of these molecular events
in vivo remains unclear, they all potentially culminate in the
development of glomerulosclerosis.
PAF functions as a chemoattractant and increases adhe-
sion of polymorphonuclear leukocytes and monocytes to
mesangial cells. The mechanism is likely to involve
b2-integrins/intercellular adhesion molecule 1 interaction.
61
Therefore, PAF promotes inﬂammatory inﬁltration of the
glomerulus.
PAF increases the expression of low-density lipoprotein
receptor and scavenger receptors in mesangial cells.64 This
causes an increased uptake of lipids and their accumulation in
mesangial cells, leading to the formation of foam cells.
Mesangial lipid accumulation is widely recognized as an
important stage of glomerulosclerosis and a key factor that
participates in the initiation and progression of lipid-mediated
renal injury.72e75
Mesangial cells possess a well-developed actin, myosin,
and tropomyosin cytoskeleton that renders them contrac-
tile.76 This property is of major importance for mesangial
cells in their function of regulating glomerular hemody-
namics by changing the geometry of capillary loops.77e79
PAF induces mesangial cell contraction56,67e71 through
increase in intracellular calcium69,71,80,81 and cytoskeletal
reorganization.56,68 In addition, because exogenously added892synthetic PAF directly induces mesangial cell contraction,
some cytokines recapitulate PAF effects on mesangial cell
shape change. Accordingly, endogenously generated PAF
serves as a secondary mediator of the effects on mesangial
cell shape of IL-12,56 endothelin,70 and TNF.68 A functional
consequence of mesangial contraction in vivo is likely to be
a change in GFR, because it re-proportions blood volume
within a capillary network and therefore affects glomerular
hydrostatic pressure, ultraﬁltration surface area, and GFR.78
However, mesangial cell contraction is the ﬁrst step that
leads to matrix overproduction. Sustained cell deformation
creates mechanical stress to which mesangial cells respond
by generating soluble factors such as TGF-b, vascular
endothelial growth factor, and connective tissue growth
factor, causing matrix overproduction that results in
mesangial expansion and glomerulosclerosis.82e84
Similar to the effect on interstitial ﬁbroblasts and renal
tubular epithelial cells,51 PAF up-regulates extracellular
matrix components in cultured rat and human mesangial
cells.50 Speciﬁcally, the stimulatory effect is observed on
ﬁbronectin and type IV collagen expression. For ﬁbronectin,
the induction of the mRNA transcription was accompanied
by the increased protein production. Preceding the induction
of the matrix components, PAF triggers the production of
TGF-b and also stimulates activation of the latent TGF-b.
Therefore, the molecular cascade through which PAF might
participate in the mesangial matrix accumulation duringajp.amjpathol.org - The American Journal of Pathology
PAF and Mesangial Cellsglomerular injury is likely to be mediated by autocrine TGF-
b. In agreement with these in vitro data, our group has
previously found mesangial matrix expansion in mouse
inbred strains to be associated with Far2, a gene coding for
an enzyme fatty acyl-CoA reductase 2 that catalyzes pro-
duction of fatty alcohols which may subsequently be used
for PAF synthesis.85 These results not only support the link
between PAF and mesangial matrix overproduction but also
open potential future research direction that aims to identify
additional enzymes and intermediate products of the PAF
biosynthetic pathways.
Mesangioproliferation is widely recognized as a process
underlying many types of glomerular injury, such as
mesangial expansion, sclerosis, and glomerulonephritis.
Reports are controversial on the relation between PAF and
mesangial cell hyperplasia. PAF does not induce prolifera-
tion in cultured mesangial cells50,64; however, some other
studies report otherwise.86 Our own unpublished data sup-
port the notion of PAF having no effect on proliferation of
mesangial cells. However, in renal carcinomas, PAF may
mediate the mitogenic effect of CD154.61
Cross-Talk between Mesangial Cells and Podocytes
It is unclear whether podocytes are also capable of PAF
synthesis. Cultured podocytes do not produce PAF even on
stimulation with calcium ionophore, IgG, IL-1b, or
TNF-a55; however, some studies report PAF production by
TNF-aestimulated podocytes.87 However, there is a
consensus that podocytes are a target of PAF because they
express PAFR. PAF effects on podocytes include loss of
nephrin,87 cytoskeletal rearrangements, and decreased
proteoglycan production,29 leading to a decrease in anionic
charge of the glomerular basement membrane and,
consequently, loss of its charge selectivity. A cross-talk
between mesangial cells and podocytes is postulated as a
mechanism responsible for the development of protein-
uria.77 PAF might be one of the cytokines released by
mesangial cells that mediate their communication with
podocytes.87
Therapeutic Approaches
PAF Receptor Antagonists
The targeting of the PAF pathway and the exploration of
therapeutic possibilities are mostly focused on the PAF-
PAFR interaction. Many antagonists are described that can
competitively or noncompetitively displace PAF from its
binding sites. These antagonists are mostly studied in the
context of asthma and allergy88 but also in models for
cardiovascular disease,89 psoriasis,90 and kidney injury.
Treatment with the antagonist WEB2170 in a rat model of
mesangial cell injury ameliorates the loss in GFR and reduces
structural damage in nephritic glomeruli.91 The same antag-
onist was recently used in a unilateral ureter obstructionThe American Journal of Pathology - ajp.amjpathol.orgmodel. Treatment of mice with WEB2170 at the ﬁrst 3 days
after unilateral ureter obstruction leads to a decrease in pro-
teinuria, lowers levels of urinary NGAL, and reduces
expression of the proﬁbrotic markers TFG-b and type 1
collagen.36
PAF Acetylhydrolase Activation
Another possible target for therapy that has been explored is
an increase in PAF acetylhydrolase, the enzyme that cata-
lyzes the degradation of active PAF. Rats pretreated with
recombinant PAF acetylhydrolase have decreased footpad
edema and vascular leakage after PAF injection.92 Additional
studies have shown beneﬁcial effects in mouse models for
sepsis,93 pancreatitis,94 atherosclerosis,95 and diabetes,96 but
no effects on the kidney are reported yet.
PAF Production
Our recent ﬁndings that increased Far2 expression is asso-
ciated with mesangial matrix expansion, likely through
increased PAF production,85 open the possibility for target-
ing this pathway. Intervention studies in which FAR2 activity
is down-regulated are under way.
Concluding Remarks and Future Directions
Numerous studies have implicated PAF in the pathogenesis
of renal diseases because of its detrimental effects on
virtually all aspects of kidney functions (Figure 4). How-
ever, a plausible beneﬁcial role of PAF in modulating
normal physiologic processes should not be overlooked and
commands separate investigation. A number of questions on
the basic biology of PAF in the context of renal patho-
physiology remain to be answered. The information gaps
and inconsistencies identiﬁed in this review include i) which
additional enzymes and potential intermediate products of
the PAF biosynthetic pathways operate in mesangial cells?,
ii) how are PAF secretion and degradation regulated under
normal and pathophysiologic conditions?, iii) what are the
effects of PAF on the other components of mesangial
matrix?, and iv) does PAF induce mesangioproliferation?
Answering these questions is of importance, because it
would navigate prospective intervention efforts to develop
PAF-targeting therapies.
Recent works suggest that biological activity of PAF may
not be conﬁned to an exclusively proinﬂammatory function,
but it might be involved in a large variety of processes.
Renal phenotyping of the available PAFR transgenic and
knockout mouse models is warranted because it might
provide insights into the role that PAF plays in the kidney.
Despite the structural variety of PAF molecular species,
most studies were limited to characterizing only 16:0- and
18:0-alkylePAF forms. These species are also the mainstay in
the anti-PAF drug development. Consequently, little is known
about other PAF variants. The biological and pathophysiologic893
Reznichenko and Korstanjesigniﬁcance of the full range of molecular composition of the
biosynthesized PAF, such as the balance in constitutive and
inducible production of PAF species in health and disease
states and its potential cell-type speciﬁcity, need to be
addressed in future studies, because the nature of the PAF
molecular composition may well orchestrate the character,
severity, course, and outcome of PAF-mediated renal disease.References
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